Celgene International Sárl (CELG) Release: Initial Phase 3 Results of the FIRST® Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at American Society of Hematology Annual Meeting
11/7/2013 10:13:27 AM
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that data from FIRST® (Frontline Investigation of Lenalidomide + Dexamethasone Versus Standard Thalidomide), its phase III study (MM-020/IFM 07-01) of REVLIMID® (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) ineligible for stem cell transplant will be presented on Sunday, Dec. 8 during the plenary session of the 55th American Society of Hematology annual meeting in New Orleans, La.
Help employers find you! Check out all the jobs and post your resume.
comments powered by